Finally, their results showed that the combination therapy of Arc and quercetin increased the inhibitory effect of this drug on the growth of androgen-dependent prostate cancer cells, which was associated with increased regulation of several signaling pathways, including the AR and PI3K/Akt pathways (161). The gene discussed is ARC; the disease is prostate carcinoma.